AbbVie: You’re Upgrading It…Now?

Cowen upgraded the drug maker to an Outperform, arguing that the stock can still reach $105 a share even after it posted a 47% rise over the past 12 months. Here’s why.
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>